Serum-biomarker-based population screening model for hepatocellular carcinoma

基于血清生物标志物的肝细胞癌人群筛查模型

阅读:1

Abstract

Hepatocellular carcinoma (HCC) early identification is crucial for improving patient outcomes. Current screening methods are often complex and costly. This study developed a simplified, cost-effective HCC screening model using serum marker data. A diverse study population from two Chinese hospitals was recruited, including cancer patients, hospital patients, and healthy individuals. A two-stage screening model was created: LASSO logistic regression for preliminary screening, followed by logistic regression incorporating alpha-fetoprotein (AFP). The model's performance was evaluated in multiple cohorts. Across five populations, the model showed strong performance with AUC-ROC ranging from 0.868 to 0.907, accuracy between 87.43% and 96.96%, and sensitivity over 75% with specificity above 90%. Compared with solely AFP models, the second-stage model improved HCC risk estimates in healthy populations, with significantly higher AUC (0.930 vs. 0.827) and net reclassification improvement (NRI) up to 56.2%. This two-stage model offers a practical, cost-efficient tool for early HCC detection, addressing a significant public health need.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。